Showing papers by "Randall B. Lauffer published in 1998"
TL;DR: As the first gadolinium-based blood pool agent in human trials, MS-325 has the potential to enhance both dynamic and steady-state MR angiograms and provides vascular signal enhancement superior to that provided with other agents.
Abstract: PURPOSE: To evaluate the protein-binding and signal enhancement characteristics of MS-325, a gadolinium-based magnetic resonance (MR) imaging blood pool agent that binds to albumin, and compare results with those obtained with existing gadolinium- and iron oxide-based agents. MATERIALS AND METHODS: Protein binding in human plasma was measured by means of ultrafiltration. T1 relaxation times (20 MHz) were measured in human plasma or ex vivo samples from rabbits and monkeys injected with 0.1 mmol of MS-325 per kilogram of body weight. Imaging (three-dimensional fast imaging with steady-state precession, or FISP) was performed at 1.0 T in phantoms, which contained varying concentrations of different agents, or rabbits after injection of 0.015-0.100 mmol/kg MS-325. RESULTS: MS-325 is 80%-96% bound in human plasma and exhibits a relaxivity approximately six to 10 times that of gadolinium diethylenetriaminepentaacetic acid (DTPA). Images of phantoms containing MS-325 were significantly brighter than those conta...
446 citations
TL;DR: This study supports further evaluation of the utility of MS‐325 in improving coronary MR angiography in humans and indicates that the blood signal‐to‐noise ratio increased, depending on the region of interest in which theBlood signal was measured and the precontrast imaging sequence structures.
Abstract: To assess the effectiveness of an intravascular contrast agent, MS-325, for enhancing the vascular signal in coronary MR angiograms, six minipigs were studied using a three-dimensional, gradient-echo sequence with retrospective respiratory gating. To suppress the myocardial signal, preparatory RF pulses were applied before data acquisition. With the administration of MS-325, the blood signal-to-noise ratio increased by 97-276%, depending on the region of interest in which the blood signal was measured and the precontrast imaging sequence structures. The blood/myocardium contrast-to-noise ratio also significantly increased. High-resolution images (0.58 x 0.58 x 1 mm3) obtained from postmortem pig hearts demonstrated the potential delineation of coronary arteries with MS-325. In conclusion, this study supports further evaluation of the utility of MS-325 in improving coronary MR angiography in humans.
114 citations
Patent•
24 Sep 1998
TL;DR: In this article, a contrast-enhanced diagnostic imaging method for monitoring the efficacy of interventional therapies is proposed, which consists of an imageenhancing moiety and a state-dependent tissue binding moiety.
Abstract: The present invention relates to a contrast-enhanced diagnostic imaging method for monitoring the efficacy of interventional therapies. The contrast agents useful in this method comprise an image-enhancing moiety (IEM) and a state-dependent tissue binding moiety (SDTBM). These contrast agents exhibit state-dependent binding to one or more components of a targeted tissue or tissue component and provide a detectable change in the signal characteristics of the agent once bound to the targeted tissue. As a result, these agents exhibit a binding affinity for, and thus image contrast of, the targeted tissue which changes as the tissue-state changes during therapy.
30 citations